Low-variance RNAs identify Parkinson's disease molecular signature in blood

Movement Disorders

Volumn 30, Issue 6, 2015, Pages 813-821

  Chikina, Maria D ^a   Gerald, Christophe P ^a   Li, Xianting ^a   Ge, Yongchao ^a   Pincas, Hanna ^a   Nair, Venugopalan D ^a   Wong, Aaron K ^b   Krishnan, Arjun ^b   Troyanskaya, Olga G ^b   Raymond, Deborah ^c   Saunders Pullman, Rachel ^c   Bressman, Susan B ^c   Yue, Zhenyu ^a   Sealfon, Stuart C ^a  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^b Princeton University   (United States)

^c Mount Sinai Beth Israel   (United States)

Author keywords

Blood; Functional genomics; Low coefficient of variation markers; LRRK2 mutation; Parkinson's disease

Indexed keywords

INTERLEUKIN 1BETA; LEUCINE RICH REPEAT KINASE 2; LEVODOPA; MESSENGER RNA; MYELOID DIFFERENTIATION FACTOR 88; SERUM AND GLUCOCORTICOID REGULATED KINASE 1; TRANSFORMING GROWTH FACTOR BETA1; BIOLOGICAL MARKER; LRRK2 PROTEIN, HUMAN; PROTEIN SERINE THREONINE KINASE;

ADAPTIVE IMMUNITY; ADULT; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; ASHKENAZI JEW; BLOOD ANALYSIS; BLOOD SAMPLING; CLINICAL ARTICLE; CLINICAL FEATURE; CONTROLLED STUDY; DRUG EFFECT; EARLY DIAGNOSIS; FEMALE; FIRST DEGREE RELATIVE; FUNCTIONAL GENOMICS; GENE EXPRESSION; GENE EXPRESSION PROFILING; GENE IDENTIFICATION; GENE MUTATION; GENE OVEREXPRESSION; GENETIC ASSOCIATION; GENETIC TRANSCRIPTION; GENETIC VARIABILITY; GENOTYPE; HUMAN; INNATE IMMUNITY; MALE; MOLECULAR DIAGNOSIS; MOUSE; NONHUMAN; ONSET AGE; PARKINSON DISEASE; PATHOGENESIS; PRIORITY JOURNAL; RNA ANALYSIS; RNA ISOLATION; SIGNAL TRANSDUCTION; TRANSCRIPTOMICS; UNIFIED PARKINSON DISEASE RATING SCALE; VENOUS BLOOD; AGED; ANIMAL; BLOOD; CASE CONTROL STUDY; GENETIC PREDISPOSITION; GENETICS; HETEROZYGOTE; JEW; MIDDLE AGED; MUTATION; TRANSGENIC MOUSE; VERY ELDERLY;

AGED; AGED, 80 AND OVER; ANIMALS; BIOMARKERS; CASE-CONTROL STUDIES; EARLY DIAGNOSIS; FEMALE; GENE EXPRESSION; GENETIC PREDISPOSITION TO DISEASE; HETEROZYGOTE; HUMANS; JEWS; LEUCINE-RICH REPEAT SERINE-THREONINE PROTEIN KINASE-2; MALE; MICE; MICE, TRANSGENIC; MIDDLE AGED; MUTATION; PARKINSON DISEASE; PROTEIN-SERINE-THREONINE KINASES; RNA, MESSENGER;

EID: 84929654139     PISSN: 08853185     EISSN: 15318257     Source Type: Journal    
DOI: 10.1002/mds.26205     Document Type: Article

References (61)

1. Meara J, Bhowmick BK, Hobson P. Accuracy of diagnosis in patients with presumed Parkinson's disease. Age Ageing 1999;28:99-102.
2. Corti O, Lesage S, Brice A. What genetics tells us about the causes and mechanisms of Parkinson's disease. Physiol Rev 2011;91:1161-1218.
3. Haas BR, Stewart TH, Zhang J. Premotor biomarkers for Parkinson's disease-a promising direction of research. Transl Neurodegener 2012;1:11.
4. Kang JH, Irwin DJ, Chen-Plotkin AS, et al. Association of cerebrospinal fluid beta-amyloid 1-42, T-tau, P-tau181, and alpha-synuclein levels with clinical features of drug-naive patients with early Parkinson disease. JAMA Neurol 2013;70:1277-1287.
5. Molochnikov L, Rabey JM, Dobronevsky E, et al. A molecular signature in blood identifies early Parkinson's disease. Mol Neurodegener 2012;7:26.
6. Mutez E, Larvor L, Lepretre F, et al. Transcriptional profile of Parkinson blood mononuclear cells with LRRK2 mutation. Neurobiol Aging 2011;32:1839-1848.
7. Mutez E, Nkiliza A, Belarbi K, et al. Involvement of the immune system, endocytosis and EIF2 signaling in both genetically determined and sporadic forms of Parkinson's disease. Neurobiol Dis 2014;63:165-170.
8. Scherzer CR, Eklund AC, Morse LJ, et al. Molecular markers of early Parkinson's disease based on gene expression in blood. Proc Natl Acad Sci U S A 2007;104:955-960.
9. Shadrina MI, Filatova EV, Karabanov AV, et al. Expression analysis of suppression of tumorigenicity 13 gene in patients with Parkinson's disease. Neurosci Lett 2010;473:257-259.
10. Shehadeh LA, Yu K, Wang L, et al. SRRM2, a potential blood biomarker revealing high alternative splicing in Parkinson's disease. PloS One 2010;5:e9104.
11. Chikina MD, Sealfon SC. Increasing consistency of disease biomarker prediction across datasets. PloS One 2014;9:e91272.
12. Antonijevic I, Tamm J, Artymyshyn R, et al. 2010. System and methods for measuring biomarker profiles. PCT Int. Patent Application WO 2010/025216.
13. Fortina P, Surrey S. Digital mRNA profiling. Nat Biotechnol 2008;26:293-294.
14. Li X, Patel JC, Wang J, et al. Enhanced striatal dopamine transmission and motor performance with LRRK2 overexpression in mice is eliminated by familial Parkinson's disease mutation G2019S. J Neurosci 2010;30:1788-1797.
15. Lin X, Parisiadou L, Gu XL, et al. Leucine-rich repeat kinase 2 regulates the progression of neuropathology induced by Parkinson's-disease-related mutant alpha-synuclein. Neuron 2009;64:807-827.
16. Hughes AJ, Daniel SE, Kilford L, et al. Accuracy of clinical diagnosis of idiopathic Parkinson's disease: a clinico-pathological study of 100 cases. J Neurol Neurosurg Psychiatry 1992;55:181-184.
17. Geiss GK, Bumgarner RE, Birditt B, et al. Direct multiplexed measurement of gene expression with color-coded probe pairs. Nat Biotechnol 2008;26:317-325.
18. Bland JM, Altman DG. Statistical methods for assessing agreement between two methods of clinical measurement. Lancet 1986;1:307-310.
19. Dudoit S, Yang YH, Callow MJ, et al. Statistical methods for identifying differentially expressed genes in replicated cDNA microarray experiments. Stat Sinica 2002;12:111-139.
20. Cleveland WS. Robust locally weighted regression and smoothing scatterplots. J Am Stat Assoc 1979;74:829-336.
21. Cleveland WS. Lowess-a program for smoothing scatterplots by robust locally weighted regression. Am Stat 1981;35:54-54.
22. Dabney A, Storey JD, qvalue Tutorial PRS, et al. Q-value estimation for false discovery rate control. Medicine 2004;344:539-548.
23. Taxman DJ, Holley-Guthrie EA, Huang MT, et al. The NLR adaptor ASC/PYCARD regulates DUSP10, mitogen-activated protein kinase (MAPK), and chemokine induction independent of the inflammasome. J Biol Chem 2011;286:19605-19616.
24. Zhou F, Zhang X, van Dam H, et al. Ubiquitin-specific protease 4 mitigates Toll-like/interleukin-1 receptor signaling and regulates innate immune activation. J Biol Chem 2012;287:11002-11010.
25. Wang L, Zhao W, Zhang M, et al. USP4 positively regulates RIG-I-mediated antiviral response through deubiquitination and stabilization of RIG-I. J Virol 2013;87:4507-4515.
26. Sotiropoulou G, Pampalakis G, Diamandis EP. Functional roles of human kallikrein-related peptidases. J Biol Chem 2009;284:32989-32994.
27. Zinger A, Barcia C, Herrero MT, et al. The involvement of neuroinflammation and kynurenine pathway in Parkinson's disease. Parkinsons Dis 2011;2011:716859.
28. Li X, Ranjith-Kumar CT, Brooks MT, et al. The RIG-I-like receptor LGP2 recognizes the termini of double-stranded RNA. J Biol Chem 2009;284:13881-13891.
29. Liu SB, Mi WL, Wang YQ. Research progress on the NLRP3 inflammasome and its role in the central nervous system. Neurosci Bull 2013;29:779-787.
30. Zhu J, Mohan C. Toll-like receptor signaling pathways-therapeutic opportunities. Mediators Inflamm 2010;2010:781235.
31. Bommireddy R, Doetschman T. TGFbeta1 and Treg cells: alliance for tolerance. Trends Mol Med 2007;13:492-501.
32. Das ND, Jung KH, Choi MR, et al. Gene networking and inflammatory pathway analysis in a JMJD3 knockdown human monocytic cell line. Cell Biochem Funct 2012;30:224-232.
33. Wu J, Lou H, Alerte TN, et al. Lewy-like aggregation of alpha-synuclein reduces protein phosphatase 2A activity in vitro and in vivo. Neuroscience 2012;207:288-297.
34. Saraceno C, Marcello E, Di Marino D, et al. SAP97-mediated ADAM10 trafficking from Golgi outposts depends on PKC phosphorylation. Cell Death Dis 2014;5:e1547.
35. Suh J, Choi SH, Romano DM, et al. ADAM10 missense mutations potentiate beta-amyloid accumulation by impairing prodomain chaperone function. Neuron 2013;80:385-401.
36. Nisole S, Stoye JP, Saib A. TRIM family proteins: retroviral restriction and antiviral defence. Nature reviews Microbiology 2005;3:799-808.
37. Fan HP, Di Liao C, Fu BY, et al. Interindividual and interethnic variation in genomewide gene expression: insights into the biological variation of gene expression and clinical implications. Clin Chem 2009;55:774-785.
38. Peters EH, Rojas-Caro S, Brigell MG, et al. Quality-controlled measurement methods for quantification of variations in transcript abundance in whole blood samples from healthy volunteers. Clin Chem 2007;53:1030-1037.
39. Hamza TH, Zabetian CP, Tenesa A, et al. Common genetic variation in the HLA region is associated with late-onset sporadic Parkinson's disease. Nat Genet 2010;42:781-785.
40. International Parkinson Disease Genomics Consortium, Nalls MA, Plagnol V, et al. Imputation of sequence variants for identification of genetic risks for Parkinson's disease: a meta-analysis of genome-wide association studies. Lancet 2011;377:641-649.
41. Sullivan PF, Fan C, Perou CM. Evaluating the comparability of gene expression in blood and brain. Am J Med Genet B Neuropsychiatr Genet 2006;141B:261-268.
42. Dzamko N, Inesta-Vaquera F, Zhang J, et al. The IkappaB kinase family phosphorylates the Parkinson's disease kinase LRRK2 at Ser935 and Ser910 during Toll-like receptor signaling. PLoS One 2012;7:e39132.
43. Liu B, Dai J, Zheng H, et al. Cell surface expression of an endoplasmic reticulum resident heat shock protein gp96 triggers MyD88-dependent systemic autoimmune diseases. Proc Natl Acad Sci U S A 2003;100:15824-15829.
44. Marshak-Rothstein A. Toll-like receptors in systemic autoimmune disease. Nat Rev Immunol 2006;6:823-835.
45. Cebrián C, Zucca FA, Mauri P, et al. MHC-I expression renders catecholaminergic neurons susceptible to T-cell-mediated degeneration. Nat Commun 2014;5:3633.
46. Monahan AJ, Warren M, Carvey PM. Neuroinflammation and peripheral immune infiltration in Parkinson's disease: an autoimmune hypothesis. Cell Transplant 2008;17:363-372.
47. Li X, Sundquist J, Sundquist K. Subsequent risks of Parkinson disease in patients with autoimmune and related disorders: a nationwide epidemiological study from Sweden. Neurodegener Dis 2012;10:277-284.
48. Pattarini R, Rong Y, Shepherd KR, et al. Long-lasting transcriptional refractoriness triggered by a single exposure to 1-methyl-4-phenyl-1, 2, 3, 6-tetrahydropyrimidine. Neuroscience 2012;214:84-105.
49. Twine NA, Janitz K, Wilkins MR, et al. Whole transcriptome sequencing reveals gene expression and splicing differences in brain regions affected by Alzheimer's disease. PLoS One 2011;6:e16266.
50. Mogi M, Kondo T, Mizuno Y, et al. p53 protein, interferon-gamma, and NF-kappaB levels are elevated in the parkinsonian brain. Neurosci Lett 2007;414:94-97.
51. Shimoji M, Pagan F, Healton EB, et al. CXCR4 and CXCL12 expression is increased in the nigro-striatal system of Parkinson's disease. Neurotox Res 2009;16:318-328.
52. Brochard V, Combadière B, Prigent A, et al. Infiltration of CD4+ lymphocytes into the brain contributes to neurodegeneration in a mouse model of Parkinson disease. J Clin Invest 2009;119:182-192.
53. Noelker C, Morel L, Lescot T, et al. Toll like receptor 4 mediates cell death in a mouse MPTP model of Parkinson disease. Sci Rep 2013;3:1393.
54. Junn E, Mouradian MM. MicroRNAs in neurodegenerative disorders. Cell Cycle 2010;9:1717-1721.
55. McHugh D, Hu SS, Rimmerman N, et al. N-arachidonoyl glycine, an abundant endogenous lipid, potently drives directed cellular migration through GPR18, the putative abnormal cannabidiol receptor. BMC Neurosci 2010;11:44.
56. Lee Y, Hur I, Park SY, et al. The role of PACT in the RNA silencing pathway. EMBO J 2006;25:522-532.
57. Mouradian MM. MicroRNAs in Parkinson's disease. Neurobiol Dis 2012;46:279-284.
58. Gehrke S, Imai Y, Sokol N, et al. Pathogenic LRRK2 negatively regulates microRNA-mediated translational repression. Nature 2010;466:637-641.
59. Nikonova EV, Xiong Y, Tanis KQ, et al. Transcriptional responses to loss or gain of function of the leucine-rich repeat kinase 2 (LRRK2) gene uncover biological processes modulated by LRRK2 activity. Hum Mol Genet 2012;21:163-174.
60. Orenstein SJ, Kuo SH, Tasset I, et al. Interplay of LRRK2 with chaperone-mediated autophagy. Nat Neurosci 2013;16:394-406.
61. Greene CS, Krishnan A, Wong AK, et al. Understanding multicellular function and disease with human tissue-specific networks. Nature genetics Accepted for publication 2015.